Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial

Volume: 58, Pages: 65
Published: Jan 1, 2017
Abstract
No abstract.
Paper Details
Title
Regorafenib as second-line treatment for patients with HCC who progressed on sorafenib: Japanese subgroup analysis of phase 3 RESORCE trial
Published Date
Jan 1, 2017
Journal
Volume
58
Pages
65
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.